中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (4): 347-351.doi: 10.35541/cjd.20200429

• 研究报道 • 上一篇    下一篇

SLC35E1和SLC35E2B蛋白在分枝杆菌感染性疾病皮损中的表达

颜韵灵    郑宝庆    何雪瑜    程庆    王晓华   

  1. 南方医科大学皮肤病医院，广州  510091
  • 收稿日期:2020-05-06 修回日期:2020-10-11 发布日期:2021-03-31
  • 通讯作者: 程庆；王晓华 E-mail:chengqinghappy@163.com; wxh_21773@163.com
  • 基金资助:
    广东省医学科研基金（A2018316）；广东省科技创新战略专项资金项目（2018A0303130318）

Expression of solute carrier proteins SLC35E1 and SLC35E2B in skin lesions of patients with Mycobacterium infections

Yan Yunling, Zheng Baoqing, He Xueyu, Cheng Qing, Wang Xiaohua   

  1. Dermatology Hospital of Southern Medical University, Guangzhou 510091, China
  • Received:2020-05-06 Revised:2020-10-11 Published:2021-03-31
  • Contact: Cheng Qing; Wang Xiaohua E-mail:chengqinghappy@163.com; wxh_21773@163.com
  • Supported by:
    Medical Research Fund of Guangdong Province（A2018316）; Science and Technology Innovation Strategy Special Fund Project of Guangdong Province （2018A0303130318）

PDF

25

PDF (Mobile)

0

摘要： 【摘要】 目的 观察溶质转运家族35E1（SLC35E1）和SLC35E2B蛋白在分枝杆菌感染患者皮损中的表达。方法 收集2014—2018年南方医科大学皮肤病医院确诊为分枝杆菌感染患者的石蜡包埋皮损组织，其中多菌型麻风患者10例，非结核分枝杆菌感染9例，皮肤结核7例，硬红斑5例，同时收集10例健康人石蜡包埋皮损组织作为正常对照组。免疫组化染色分析SLC35E1、SLC35E2B在上述皮损及正常对照组中的表达差异。免疫荧光染色检测CD68、S100与SLC35E1、SLC35E2B蛋白在皮损组织中的共表达情况。结果 正常对照组不表达SLC35E1、SLC35E2B，但麻风、非结核分枝杆菌感染、皮肤结核及硬红斑患者皮损真皮中二者的表达显著增高。免疫组化染色显示多菌型麻风组、非结核分枝杆菌组、皮肤结核组、硬红斑组皮损组织SLC35E1表达水平（平均光密度）分别为0.143 ± 0.010、0.278 ± 0.015、0.171 ± 0.010、0.200 ± 0.015，SLC35E2B为0.169 ± 0.004、0.229 ± 0.088、0.103 ± 0.016、0.118 ± 0.021，均较正常对照组（均为0）显著升高（P < 0.05）。免疫荧光染色结果显示，麻风、非结核分枝杆菌感染、皮肤结核皮损SLC35E1、SLC35E2B与CD68表达重叠。结论 SLC35E1、SLC35E2B在分枝杆菌感染性疾病皮损中表达显著增高。

关键词: 分枝杆菌属, 结核, 麻风, 非结核分枝杆菌, 溶质转运蛋白35E1, 溶质转运蛋白35E2B

Abstract: 【Abstract】 Objective To investigate the expression of solute carrier family 35 member E1 （SLC35E1） and SLC35E2B in skin lesions of patients with Mycobacterium infections. Methods Paraffin-embedded skin tissues of 31 patients confirmedly diagnosed with Mycobacterium infections were collected from Dermatology Hospital of Southern Medical University from 2014 to 2018, including 10 cases of multibacillary leprosy, 9 of nontuberculous mycobacterial infection, 7 of cutaneous tuberculosis, and 5 of erythema induratum. Meanwhile, paraffin-embedded skin tissues of 10 healthy individuals were collected, and served as normal control group. Immunohistochemical staining was performed to determine the expression of SLC35E1 and SLC35E2B in the lesional and normal control skin specimens, and immunofluorescence staining to observe the co-expression of CD68 and S100 with SLC35E1 and SLC35E2B in the skin lesions. Results Neither SLC35E1 nor SLC35E2B was expressed in the normal control group, but high expression of SLC35E1 and SLC35E2B was observed in the dermis of skin lesions from the patients with leprosy, nontuberculous mycobacterial infection, cutaneous tuberculosis or erythema induratum. Immunohistochemical staining showed that the expression of SLC35E1 and SLC35E2B （expressed as average optical density） was significantly higher in the multibacillary leprosy group （0.143 ± 0.010, 0.169 ± 0.004, respectively）, nontuberculous mycobacterial infection group （0.278 ± 0.015, 0.229 ± 0.088, respectively）, cutaneous tuberculosis group （0.171 ± 0.010, 0.103 ± 0.016, respectively） and erythema induratum group （0.200 ± 0.015, 0.118 ± 0.021, respectively） than in the normal control group （both 0, all P < 0.05）. Immunofluorescence staining showed co-expression of SLC35E1 and SLC35E2B with CD68 in skin lesions of the patients with leprosy, nontuberculous mycobacterial infection, cutaneous tuberculosis. Conclusion Both SLC35E1 and SLCE2B were markedly highly expressed in skin lesions of patients with Mycobacterium infections.

Key words: Mycobacterium, Tuberculosis, Leprosy, Nontuberculous mycobacteria, Solute carrier family 35, member E1, Solute carrier family 35, member E2B